Monopar Therapeutics Inc (MNPR)
0.7272
+0.07
(+10.18%)
USD |
NASDAQ |
May 03, 16:00
0.7272
0.00 (0.00%)
After-Hours: 20:00
Monopar Therapeutics Research and Development Expense (Quarterly): 1.036M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.036M |
| September 30, 2023 | 1.316M |
| June 30, 2023 | 1.595M |
| March 31, 2023 | 1.653M |
| December 31, 2022 | 2.103M |
| September 30, 2022 | 1.732M |
| June 30, 2022 | 2.078M |
| March 31, 2022 | 1.678M |
| December 31, 2021 | 1.983M |
| September 30, 2021 | 1.827M |
| June 30, 2021 | 1.476M |
| March 31, 2021 | 1.207M |
| December 31, 2020 | 1.632M |
| September 30, 2020 | 1.256M |
| Date | Value |
|---|---|
| June 30, 2020 | 0.8325M |
| March 31, 2020 | 0.3444M |
| December 31, 2019 | 0.5838M |
| September 30, 2019 | 0.2198M |
| June 30, 2019 | 0.3293M |
| March 31, 2019 | 0.8356M |
| December 31, 2018 | 0.521M |
| September 30, 2018 | 0.3037M |
| June 30, 2018 | 0.4926M |
| March 31, 2018 | 0.4571M |
| December 31, 2017 | 0.3093M |
| September 30, 2017 | 14.68M |
| June 30, 2017 | 0.3116M |
| March 31, 2017 | 0.1337M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.2198M
Minimum
Sep 2019
2.103M
Maximum
Dec 2022
1.310M
Average
1.476M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Motus GI Holdings Inc | 0.561M |
| SeaStar Medical Holding Corp | 1.075M |
| Perspective Therapeutics Inc | 6.08M |
| Electromed Inc | 0.107M |
| Xtant Medical Holdings Inc | 0.492M |